228 related articles for article (PubMed ID: 35069805)
1. Clinical characteristics, long-term functional outcomes and relapse of anti-LGI1/Caspr2 encephalitis: a prospective cohort study in Western China.
Guo K; Liu X; Lin J; Gong X; Li A; Liu Y; Zhou D; Hong Z
Ther Adv Neurol Disord; 2022; 15():17562864211073203. PubMed ID: 35069805
[TBL] [Abstract][Full Text] [Related]
2. Clinical features of 28 cases of anti
Feng J; Li J; Xie Y; Lü Y; Bi F; Zhou J
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Mar; 48(3):386-396. PubMed ID: 37164922
[TBL] [Abstract][Full Text] [Related]
3. Clinical features and outcomes of leucine-rich glioma-inactivated protein 1 and contactin protein-like 2 antibody-associated autoimmune encephalitis in a Chinese cohort.
Li HY; Qiao S; Cui CS; Feng F; Liu XW; Yang XD
J Clin Neurosci; 2022 Jul; 101():137-143. PubMed ID: 35597061
[TBL] [Abstract][Full Text] [Related]
4. Phenotypic Spectrum of CASPR2 and LGI1 Antibodies Associated Neurological Disorders in Children.
Jiang Y; Tan C; Li T; Song X; Ma J; Yao Z; Hong S; Li X; Jiang L; Luo Y
Front Pediatr; 2022; 10():815976. PubMed ID: 35463890
[TBL] [Abstract][Full Text] [Related]
5. Anti-LGI1, anti-GABABR, and Anti-CASPR2 encephalitides in Asia: A systematic review.
Ghimire P; Khanal UP; Gajurel BP; Karn R; Rajbhandari R; Paudel S; Gautam N; Ojha R
Brain Behav; 2020 Oct; 10(10):e01793. PubMed ID: 32783406
[TBL] [Abstract][Full Text] [Related]
6. Autoimmune encephalitis with anti-leucine-rich glioma-inactivated 1 or anti-contactin-associated protein-like 2 antibodies (formerly called voltage-gated potassium channel-complex antibodies).
Bastiaansen AEM; van Sonderen A; Titulaer MJ
Curr Opin Neurol; 2017 Jun; 30(3):302-309. PubMed ID: 28248701
[TBL] [Abstract][Full Text] [Related]
7. Seizure underreporting in LGI1 and CASPR2 antibody encephalitis.
Baumgartner T; Pitsch J; Olaciregui-Dague K; Hoppe C; Racz A; Rüber T; Becker A; von Wrede R; Surges R
Epilepsia; 2022 Sep; 63(9):e100-e105. PubMed ID: 35735209
[TBL] [Abstract][Full Text] [Related]
8. Rituximab Treatment and Long-term Outcome of Patients With Autoimmune Encephalitis: Real-world Evidence From the GENERATE Registry.
Thaler FS; Zimmermann L; Kammermeier S; Strippel C; Ringelstein M; Kraft A; Sühs KW; Wickel J; Geis C; Markewitz R; Urbanek C; Sommer C; Doppler K; Penner L; Lewerenz J; Rößling R; Finke C; Prüss H; Melzer N; Wandinger KP; Leypoldt F; Kümpfel T;
Neurol Neuroimmunol Neuroinflamm; 2021 Nov; 8(6):. PubMed ID: 34599001
[TBL] [Abstract][Full Text] [Related]
9. Distinction between anti-VGKC-complex seropositive patients with and without anti-LGI1/CASPR2 antibodies.
Yeo T; Chen Z; Yong KP; Wong PYW; Chai JYH; Tan K
J Neurol Sci; 2018 Aug; 391():64-71. PubMed ID: 30103974
[TBL] [Abstract][Full Text] [Related]
10. Serum and CSF cytokine levels mirror different neuroimmunological mechanisms in patients with LGI1 and Caspr2 encephalitis.
Körtvelyessy P; Goihl A; Guttek K; Schraven B; Prüss H; Reinhold D
Cytokine; 2020 Nov; 135():155226. PubMed ID: 32799011
[TBL] [Abstract][Full Text] [Related]
11. Long-term seizure outcomes in patients with autoimmune encephalitis: A prospective observational registry study update.
Liu X; Guo K; Lin J; Gong X; Li A; Zhou D; Hong Z
Epilepsia; 2022 Jul; 63(7):1812-1821. PubMed ID: 35357695
[TBL] [Abstract][Full Text] [Related]
12. Contemporary advances in antibody-mediated encephalitis: anti-LGI1 and anti-Caspr2 antibody (Ab)-mediated encephalitides.
Seery N; Butzkueven H; O'Brien TJ; Monif M
Autoimmun Rev; 2022 May; 21(5):103074. PubMed ID: 35247644
[TBL] [Abstract][Full Text] [Related]
13. Magnetic Resonance Imaging Characteristics of LGI1-Antibody and CASPR2-Antibody Encephalitis.
Kelly MJ; Grant E; Murchison AG; Binks S; Ramanathan S; Michael S; Handel AE; Handunnetthi L; Uy CE; Soltys JN; Dubey D; Day GS; Lopez-Chiriboga AS; Flanagan EP; Sheerin F; Irani SR
JAMA Neurol; 2024 May; 81(5):525-533. PubMed ID: 38497971
[TBL] [Abstract][Full Text] [Related]
14. Association of Leucine-Rich Glioma Inactivated Protein 1, Contactin-Associated Protein 2, and Contactin 2 Antibodies With Clinical Features and Patient-Reported Pain in Acquired Neuromyotonia.
Vincent A; Pettingill P; Pettingill R; Lang B; Birch R; Waters P; Irani SR; Buckley C; Watanabe O; Arimura K; Kiernan MC
JAMA Neurol; 2018 Dec; 75(12):1519-1527. PubMed ID: 30242309
[TBL] [Abstract][Full Text] [Related]
15. Mycophenolate mofetil reduces the risk of relapse in anti-leucine-rich glioma-inactivated protein 1 encephalitis: a prospective observational cohort study.
Liu M; Xu X; Fan S; Ren H; Zhao Y; Guan H
Neurol Sci; 2024 Jan; 45(1):253-260. PubMed ID: 37580515
[TBL] [Abstract][Full Text] [Related]
16. Sleep Disorders in Leucine-Rich Glioma-Inactivated Protein 1 and Contactin Protein-Like 2 Antibody-Associated Diseases.
Lin N; Hao H; Guan H; Sun H; Liu Q; Lu Q; Jin L; Ren H; Huang Y
Front Neurol; 2020; 11():696. PubMed ID: 32849186
[No Abstract] [Full Text] [Related]
17. Leucine-rich Glioma-inactivated 1 Encephalitis Followed by Isaacs Syndrome: Alternating Presence of Pathogenic Autoantibodies to Leucine-rich Glioma-inactivated 1 and Contactin-associated Protein-like 2.
Murayama A; Sugaya K; Hara M; Kawazoe T; Tobisawa S; Nakajima H; Takahashi K
Intern Med; 2023 Jun; 62(11):1659-1663. PubMed ID: 36223927
[TBL] [Abstract][Full Text] [Related]
18. Distinct movement disorders in contactin-associated-protein-like-2 antibody-associated autoimmune encephalitis.
Gövert F; Abrante L; Becktepe J; Balint B; Ganos C; Hofstadt-van Oy U; Krogias C; Varley J; Irani SR; Paneva S; Titulaer MJ; de Vries JM; Boon AJW; Schreurs MWJ; Joubert B; Honnorat J; Vogrig A; Ariño H; Sabater L; Dalmau J; Scotton S; Jacob S; Melzer N; Bien CG; Geis C; Lewerenz J; Prüss H; Wandinger KP; Deuschl G; Leypoldt F
Brain; 2023 Feb; 146(2):657-667. PubMed ID: 35875984
[TBL] [Abstract][Full Text] [Related]
19. A Chinese female Morvan patient with LGI1 and CASPR2 antibodies: a case report.
Zhang L; Lu Q; Guan HZ; Mei JH; Ren HT; Liu MS; Peng B; Cui LY
BMC Neurol; 2016 Mar; 16():37. PubMed ID: 26983964
[TBL] [Abstract][Full Text] [Related]
20. Clinical Features and Long-Term Outcomes of Anti-Leucine-Rich Glioma-Inactivated 1 Encephalitis: A Multi-Center Study.
Qiao S; Wu HK; Liu LL; Wang ML; Zhang RR; Han T; Liu XW
Neuropsychiatr Dis Treat; 2021; 17():203-212. PubMed ID: 33531809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
